Article (Scientific journals)
Burden of migraine in patients attending Belgian headache specialists: real-world evidence from the BECOME study.
Lourens, Shantaily; Van Deun, Laura; Peeters, Ilse et al.
2023In Acta Neurologica Belgica, 123 (4), p. 1495 - 1503
Peer Reviewed verified by ORBi
 

Files


Full Text
BECOME_Belgium.pdf
Author postprint (598.46 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Burden; Migraine; Patient-reported outcomes; Treatment failure; Humans; Belgium/epidemiology; Cross-Sectional Studies; Prospective Studies; Headache; Migraine Disorders/epidemiology; Migraine Disorders/therapy; Migraine Disorders/diagnosis; Belgium; Migraine Disorders; Neurology (clinical)
Abstract :
[en] [en] INTRODUCTION: Migraine is a primary headache disorder, which imposes a major burden on the sufferers. The BECOME study (Burden of migrainE in specialist headache Centers treating patients with prOphylactic treatMent failurE) attempted to characterize and assess the prevalence, burden and healthcare resource utilization of migraine patients presenting in specialized headache centers in Europe and Israel. In this paper, we will describe the patient characteristics of the Belgian headache centers. METHODS: The BECOME study was a prospective, non-interventional, cross-sectional study consisting of two parts. In the first part of the study, data were collected from subjects with a diagnosis of migraine. Subsequently, patients with ≥ 4 monthly migraine days (MMD) and ≥ 1 prior preventive treatment failure (PPTF) filled out validated questionnaires to assess the burden of disease. RESULTS: In part 1 of the Belgian study population (N = 806), 45% of patients reported ≥ 8 MMD and 25% had failed ≥ 4 preventive treatments. In part 2 (N = 90), more than 90% of patients reported having severe impact of headache on daily life and having severe migraine-related disability. The impact was the highest for patients with ≥ 15 MMD, however, even within the patient population with < 8 MMD, the burden was significant. Almost 40% of the study population suffered from anxiety. CONCLUSIONS: These findings in the Belgian sample of the BECOME study demonstrate the substantial burden and unmet need for the management of difficult-to-treat migraine.
Disciplines :
Neurology
Author, co-author :
Lourens, Shantaily ;  Department of Neurology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium. s.d.lourens@live.nl
Van Deun, Laura;  Department of Neurology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium
Peeters, Ilse;  Department of Neurology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium
Paemeleire, Koen;  Department of Neurology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
Van Dycke, Annelies;  Department of Neurology, General Hospital Sint-Jan Bruges, Ruddershove 10, 8000, Bruges, Belgium
De Klippel, Nina;  Department of Neurology, Jessa Ziekenhuis, Stadsomvaart 11, 3500, Hasselt, Belgium
Schoenen, Jean  ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Ritter, Shannon;  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA ; Novartis Pharma AG, Basel, Switzerland
Snellman, Josefin;  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA ; Novartis Pharma AG, Basel, Switzerland
Versijpt, Jan;  Department of Neurology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090, Brussels, Belgium
Language :
English
Title :
Burden of migraine in patients attending Belgian headache specialists: real-world evidence from the BECOME study.
Publication date :
August 2023
Journal title :
Acta Neurologica Belgica
ISSN :
0300-9009
eISSN :
2240-2993
Publisher :
Springer Science and Business Media Deutschland GmbH, Italy
Volume :
123
Issue :
4
Pages :
1495 - 1503
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
Koen Paemeleire has received personal compensation from Allergan/Abbvie, Amgen/Novartis, Eli Lilly, Lundbeck and Teva for consulting, serving on a scientific advisory board, and/or speaking and is a clinical trial investigator for Amgen/Novartis (erenumab), Eli Lilly (galcanezumab), and Autonomic Technologies Inc. (sphenopalatine ganglion stimulation). Josefin Snellman has received personal compensation from Allergan/Abbvie, Amgen/Novartis, Eli Lilly, Lundbeck, Teva, Cefaly Technology, Autonomic Technologies Inc. and Man & Science for consulting, serving on a scientific advisory board, and/or speaking and is an investigator for Eli Lilly, Novartis, Lundbeck and Teva. Shannon Ritter and Josefin Snellman are full employees of Novartis. Jan Versijpt received personal fees and nonfinancial support from Teva, personal fees from Novartis and Lundbeck, and grants and nonfinancial support from Allergan/Abbvie.This study was funded by Novartis Pharma AG, Basel, Switzerland. The study sponsor participated in the study design, data collection, data review, data analysis and writing of the report.
Available on ORBi :
since 03 December 2024

Statistics


Number of views
15 (0 by ULiège)
Number of downloads
7 (0 by ULiège)

Scopus citations®
 
0
Scopus citations®
without self-citations
0
OpenCitations
 
0
OpenAlex citations
 
0

Bibliography


Similar publications



Contact ORBi